HSCS — Stock Film
STOCK FILMSCENE 1/11HSCS · $3.39
Stock Expert AI presents
HSCS
HeartSciences Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
HeartSciences Inc. What it actually does.

Develops AI-enhanced electrocardiogram (AI-ECG) solutions for cardiac diagnostics. Now — the numbers.

on the stock market since 2022
14 employees
$7.3M market value
Revenue last year:
$4K
The loss that same year:
$9.1M
For every $1 it earns, the company spends $2118.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales have been shrinking.

An average decline of 33% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$14K
2022
2023
2024
2025
$4K
2025
In the vault right now:
$1.7B
DEBT: $3.9B
At this pace, that money lasts about 181.2 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
1,695×

This company is not turning a profit, so the market is pricing its sales instead: 1,695× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 3% of them.

Analysts' average target sits 12% below today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
5
very weak

Clearly below the class average.

FINANCIAL STRENGTH
1
very weak

Clearly below the class average.

VALUATION
3
very weak

Clearly below the class average.

GROWTH
32
very weak

Clearly below the class average.

PRICE MOMENTUM
89
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $4K a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 15 buys and 1 sell. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $9.1M against $4K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The price sits above analysts’ target

The stock trades 12% above the average analyst price target.

FINALE · THE GRADE
F
16 / 100 · MoonshotScore

On our five-subject report card, HSCS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: HSCS is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film